Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform. Leading role in authoring clinical study protocols/amendments and related study documents (including but not limited to drug specific risk language, ICFs, clinical study training materials, pharmacy manual, laboratory manual, etc.) by translating the strategy and approved concept into executable and efficient clinical studies.